CONMED Appoints New CFO John Gallagher Effective July 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2026
0mins
Source: seekingalpha
- Executive Appointment: CONMED announced the appointment of John Gallagher as CFO effective July 15, 2026, succeeding Todd Garner, who will remain as an advisor until November 2, 2026, ensuring stability during the transition period.
- Extensive Experience: Gallagher brings nearly three decades of financial expertise, having led corporate finance, investor relations, and capital market activities in public healthcare and industrial firms, which is expected to enhance CONMED's strategic financial management.
- Predecessor's Background: Prior to his role at Certara, Gallagher served as CFO at Cue Health, where he gained valuable industry knowledge and management experience, which will aid in improving CONMED's financial performance and market competitiveness.
- Growth Outlook: CONMED projects an organic growth rate of 5.0% to 6.5% for 2026 while refinancing debt, indicating that under new financial leadership, the company will continue to pursue robust growth and financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNMD
Wall Street analysts forecast CNMD stock price to rise
5 Analyst Rating
1 Buy
4 Hold
0 Sell
Hold
Current: 35.110
Low
41.00
Averages
50.00
High
55.00
Current: 35.110
Low
41.00
Averages
50.00
High
55.00
About CNMD
CONMED Corporation is a medical technology company which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product line consists of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CONMED Appoints New CFO John Gallagher Effective July 2026
- Executive Appointment: CONMED announced the appointment of John Gallagher as CFO effective July 15, 2026, succeeding Todd Garner, who will remain as an advisor until November 2, 2026, ensuring stability during the transition period.
- Extensive Experience: Gallagher brings nearly three decades of financial expertise, having led corporate finance, investor relations, and capital market activities in public healthcare and industrial firms, which is expected to enhance CONMED's strategic financial management.
- Predecessor's Background: Prior to his role at Certara, Gallagher served as CFO at Cue Health, where he gained valuable industry knowledge and management experience, which will aid in improving CONMED's financial performance and market competitiveness.
- Growth Outlook: CONMED projects an organic growth rate of 5.0% to 6.5% for 2026 while refinancing debt, indicating that under new financial leadership, the company will continue to pursue robust growth and financial health.
See More
CONMED Appoints New Chief Financial Officer
- Executive Appointment: CONMED announced the appointment of John E. Gallagher as Chief Financial Officer effective July 15, 2026, succeeding Todd Garner, who will remain as an advisor until November 2, 2026, indicating stability and continuity in the executive team.
- Extensive Experience: Gallagher brings nearly three decades of financial management experience, having served as CFO at Certara and Cue Health, which equips him with a strong background in the medical technology sector, expected to significantly support CONMED's strategic priorities.
- Strategic Value: His tenure at BD included driving growth and profitability in the medical segment, suggesting he can leverage his industry knowledge and financial leadership to help CONMED create long-term value in high-growth surgical categories.
- Future Outlook: Gallagher expressed excitement about collaborating closely with the CONMED team to enhance the company's operational and financial performance, reflecting the company's confidence and commitment to future growth.
See More
CONMED Q1 2026 Earnings Call Insights
- Strategic Divestiture: In Q1, CONMED completed the divestiture of certain GI products, strategically reallocating resources to focus on higher growth and higher-margin offerings, thereby enhancing execution and long-term shareholder value.
- Sales Performance Review: Total sales for the quarter were $317 million, a 1.3% year-over-year decline; however, excluding the impact of GI products, sales increased by 3.8% year-over-year, demonstrating resilience and growth potential in core operations.
- Profitability Analysis: Adjusted net income stood at $27.1 million, down 8.5% year-over-year, with adjusted EPS at $0.89, a 6.3% decrease; despite rising financing costs, the company maintains its full-year EPS guidance, reflecting management's confidence.
- Upgraded Future Outlook: CONMED raised its organic growth expectation for 2026 to 5.0%-6.5% and anticipates Q2 revenue between $336 million and $340 million, indicating a positive outlook on market demand.
See More
CONMED Reports Doubling of Q1 Profit, Raises Growth Outlook
- Profit Doubling: CONMED's Q1 net income surged to $13.8 million, more than doubling from $6.0 million last year, indicating successful cost control and margin improvement despite a slight decline in sales.
- Slight Sales Decline: The company's net sales fell 1.3% year-over-year to $317.0 million, primarily impacted by a $15.5 million drop from exiting certain gastroenterology products, although international revenue rose 4.7%, showcasing resilience in global markets.
- Upgraded Full-Year Outlook: CONMED raised its 2026 organic revenue growth forecast to 5.0% to 6.5%, with reported revenue expected between $1.35 billion and $1.375 billion, reflecting strong confidence in future growth.
- Strategic Focus on High-Growth Areas: CEO Patrick J. Beyer emphasized the company's commitment to concentrating resources on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair, aiming to drive long-term sustainable growth.
See More
CONMED Q1 Earnings Beat Expectations, Full-Year Outlook Raised
- Earnings Beat: CONMED reported a Q1 non-GAAP EPS of $0.89, exceeding expectations by $0.07, indicating strong market performance and boosting investor confidence.
- Slight Revenue Decline: Q1 revenue stood at $317 million, down 1.3% year-over-year but still beating expectations by $6.39 million, demonstrating the company's ability to maintain relatively stable revenue in a competitive environment.
- Upgraded Full-Year Outlook: Based on Q1 performance, the company raised its 2026 organic revenue growth forecast to 5.0% to 6.5%, up from the previous range of 4.5% to 6.0%, reflecting management's confidence in future growth.
- Positive Forex Impact: The updated revenue outlook incorporates a favorable foreign exchange impact of 40 to 50 basis points, showcasing the company's adaptability in global markets, while gastroenterology product revenue is expected to decrease to $14.5 million to $17.5 million, highlighting the necessity of strategic adjustments.
See More
CONMED Shares Enter Oversold Territory
- Oversold Signal: CONMED Corp (CNMD) saw its RSI drop to 29.4 during Monday's trading, indicating the stock has entered oversold territory, potentially attracting bullish investors looking for buying opportunities.
- Price Fluctuation: The stock price hit a low of $33.85, nearing its 52-week low of $33.21, suggesting that the recent heavy selling pressure is beginning to wane.
- Market Comparison: Compared to the current RSI of 47.6 for the S&P 500 ETF (SPY), CNMD's oversold condition may indicate an impending market sentiment reversal, prompting investors to watch for potential rebound opportunities.
- Historical Performance: With a 52-week high of $61.08 and a current trading price of $34.08, CNMD shows potential for value recovery after significant volatility, making it a stock to monitor for future gains.
See More
CONMED Appoints New CFO John Gallagher Effective July 2026
- Executive Appointment: CONMED announced the appointment of John Gallagher as CFO effective July 15, 2026, succeeding Todd Garner, who will remain as an advisor until November 2, 2026, ensuring stability during the transition period.
- Extensive Experience: Gallagher brings nearly three decades of financial expertise, having led corporate finance, investor relations, and capital market activities in public healthcare and industrial firms, which is expected to enhance CONMED's strategic financial management.
- Predecessor's Background: Prior to his role at Certara, Gallagher served as CFO at Cue Health, where he gained valuable industry knowledge and management experience, which will aid in improving CONMED's financial performance and market competitiveness.
- Growth Outlook: CONMED projects an organic growth rate of 5.0% to 6.5% for 2026 while refinancing debt, indicating that under new financial leadership, the company will continue to pursue robust growth and financial health.
See More
CONMED Appoints New Chief Financial Officer
- Executive Appointment: CONMED announced the appointment of John E. Gallagher as Chief Financial Officer effective July 15, 2026, succeeding Todd Garner, who will remain as an advisor until November 2, 2026, indicating stability and continuity in the executive team.
- Extensive Experience: Gallagher brings nearly three decades of financial management experience, having served as CFO at Certara and Cue Health, which equips him with a strong background in the medical technology sector, expected to significantly support CONMED's strategic priorities.
- Strategic Value: His tenure at BD included driving growth and profitability in the medical segment, suggesting he can leverage his industry knowledge and financial leadership to help CONMED create long-term value in high-growth surgical categories.
- Future Outlook: Gallagher expressed excitement about collaborating closely with the CONMED team to enhance the company's operational and financial performance, reflecting the company's confidence and commitment to future growth.
See More
CONMED Q1 2026 Earnings Call Insights
- Strategic Divestiture: In Q1, CONMED completed the divestiture of certain GI products, strategically reallocating resources to focus on higher growth and higher-margin offerings, thereby enhancing execution and long-term shareholder value.
- Sales Performance Review: Total sales for the quarter were $317 million, a 1.3% year-over-year decline; however, excluding the impact of GI products, sales increased by 3.8% year-over-year, demonstrating resilience and growth potential in core operations.
- Profitability Analysis: Adjusted net income stood at $27.1 million, down 8.5% year-over-year, with adjusted EPS at $0.89, a 6.3% decrease; despite rising financing costs, the company maintains its full-year EPS guidance, reflecting management's confidence.
- Upgraded Future Outlook: CONMED raised its organic growth expectation for 2026 to 5.0%-6.5% and anticipates Q2 revenue between $336 million and $340 million, indicating a positive outlook on market demand.
See More
CONMED Reports Doubling of Q1 Profit, Raises Growth Outlook
- Profit Doubling: CONMED's Q1 net income surged to $13.8 million, more than doubling from $6.0 million last year, indicating successful cost control and margin improvement despite a slight decline in sales.
- Slight Sales Decline: The company's net sales fell 1.3% year-over-year to $317.0 million, primarily impacted by a $15.5 million drop from exiting certain gastroenterology products, although international revenue rose 4.7%, showcasing resilience in global markets.
- Upgraded Full-Year Outlook: CONMED raised its 2026 organic revenue growth forecast to 5.0% to 6.5%, with reported revenue expected between $1.35 billion and $1.375 billion, reflecting strong confidence in future growth.
- Strategic Focus on High-Growth Areas: CEO Patrick J. Beyer emphasized the company's commitment to concentrating resources on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair, aiming to drive long-term sustainable growth.
See More
CONMED Q1 Earnings Beat Expectations, Full-Year Outlook Raised
- Earnings Beat: CONMED reported a Q1 non-GAAP EPS of $0.89, exceeding expectations by $0.07, indicating strong market performance and boosting investor confidence.
- Slight Revenue Decline: Q1 revenue stood at $317 million, down 1.3% year-over-year but still beating expectations by $6.39 million, demonstrating the company's ability to maintain relatively stable revenue in a competitive environment.
- Upgraded Full-Year Outlook: Based on Q1 performance, the company raised its 2026 organic revenue growth forecast to 5.0% to 6.5%, up from the previous range of 4.5% to 6.0%, reflecting management's confidence in future growth.
- Positive Forex Impact: The updated revenue outlook incorporates a favorable foreign exchange impact of 40 to 50 basis points, showcasing the company's adaptability in global markets, while gastroenterology product revenue is expected to decrease to $14.5 million to $17.5 million, highlighting the necessity of strategic adjustments.
See More
CONMED Shares Enter Oversold Territory
- Oversold Signal: CONMED Corp (CNMD) saw its RSI drop to 29.4 during Monday's trading, indicating the stock has entered oversold territory, potentially attracting bullish investors looking for buying opportunities.
- Price Fluctuation: The stock price hit a low of $33.85, nearing its 52-week low of $33.21, suggesting that the recent heavy selling pressure is beginning to wane.
- Market Comparison: Compared to the current RSI of 47.6 for the S&P 500 ETF (SPY), CNMD's oversold condition may indicate an impending market sentiment reversal, prompting investors to watch for potential rebound opportunities.
- Historical Performance: With a 52-week high of $61.08 and a current trading price of $34.08, CNMD shows potential for value recovery after significant volatility, making it a stock to monitor for future gains.
See More
